A novel anoikis-related signature predicts prognosis risk and treatment responsiveness in diffuse large B-cell lymphoma
CONCLUSION: The ARG-based signature may provide a promising direction for prognosis prediction and treatment optimization for DLBCL patients.PMID:38709202 | DOI:10.1080/14737159.2024.2351465 (Source: Expert Review of Molecular Diagnostics)
Source: Expert Review of Molecular Diagnostics - May 6, 2024 Category: Laboratory Medicine Authors: Mingze Guan Hua Zhao Qi Zhang Li Li Xiaobo Wang Bo Tang Source Type: research
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival
CONCLUSION: To our knowledge, this first, prospective US cooperative group, multicenter study demonstrates that MRDneg at Y1 after AutoHCT with lenalidomide maintenance is prognostic for improved 6-year PFS and OS. Serial MRD measurements may direct trials to test how further therapy may improve long-term PFS and OS.PMID:38701390 | DOI:10.1200/JCO.23.00934 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - May 3, 2024 Category: Cancer & Oncology Authors: Marcelo C Pasquini Paul K Wallace Brent Logan Manmeet Kaur Joseph D Tario Alan Howard Yali Zhang Claudio Brunstein Yvonne Efebera Nancy Geller Sergio Giralt Parameswaran Hari Mary M Horowitz John Koreth Amrita Krishnan Heather Landau George Somlo Nina Sha Source Type: research
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival
CONCLUSION: To our knowledge, this first, prospective US cooperative group, multicenter study demonstrates that MRDneg at Y1 after AutoHCT with lenalidomide maintenance is prognostic for improved 6-year PFS and OS. Serial MRD measurements may direct trials to test how further therapy may improve long-term PFS and OS.PMID:38701390 | DOI:10.1200/JCO.23.00934 (Source: Cancer Control)
Source: Cancer Control - May 3, 2024 Category: Cancer & Oncology Authors: Marcelo C Pasquini Paul K Wallace Brent Logan Manmeet Kaur Joseph D Tario Alan Howard Yali Zhang Claudio Brunstein Yvonne Efebera Nancy Geller Sergio Giralt Parameswaran Hari Mary M Horowitz John Koreth Amrita Krishnan Heather Landau George Somlo Nina Sha Source Type: research
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival
CONCLUSION: To our knowledge, this first, prospective US cooperative group, multicenter study demonstrates that MRDneg at Y1 after AutoHCT with lenalidomide maintenance is prognostic for improved 6-year PFS and OS. Serial MRD measurements may direct trials to test how further therapy may improve long-term PFS and OS.PMID:38701390 | DOI:10.1200/JCO.23.00934 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - May 3, 2024 Category: Cancer & Oncology Authors: Marcelo C Pasquini Paul K Wallace Brent Logan Manmeet Kaur Joseph D Tario Alan Howard Yali Zhang Claudio Brunstein Yvonne Efebera Nancy Geller Sergio Giralt Parameswaran Hari Mary M Horowitz John Koreth Amrita Krishnan Heather Landau George Somlo Nina Sha Source Type: research
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival
CONCLUSION: To our knowledge, this first, prospective US cooperative group, multicenter study demonstrates that MRDneg at Y1 after AutoHCT with lenalidomide maintenance is prognostic for improved 6-year PFS and OS. Serial MRD measurements may direct trials to test how further therapy may improve long-term PFS and OS.PMID:38701390 | DOI:10.1200/JCO.23.00934 (Source: Cancer Control)
Source: Cancer Control - May 3, 2024 Category: Cancer & Oncology Authors: Marcelo C Pasquini Paul K Wallace Brent Logan Manmeet Kaur Joseph D Tario Alan Howard Yali Zhang Claudio Brunstein Yvonne Efebera Nancy Geller Sergio Giralt Parameswaran Hari Mary M Horowitz John Koreth Amrita Krishnan Heather Landau George Somlo Nina Sha Source Type: research
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival
CONCLUSION: To our knowledge, this first, prospective US cooperative group, multicenter study demonstrates that MRDneg at Y1 after AutoHCT with lenalidomide maintenance is prognostic for improved 6-year PFS and OS. Serial MRD measurements may direct trials to test how further therapy may improve long-term PFS and OS.PMID:38701390 | DOI:10.1200/JCO.23.00934 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - May 3, 2024 Category: Cancer & Oncology Authors: Marcelo C Pasquini Paul K Wallace Brent Logan Manmeet Kaur Joseph D Tario Alan Howard Yali Zhang Claudio Brunstein Yvonne Efebera Nancy Geller Sergio Giralt Parameswaran Hari Mary M Horowitz John Koreth Amrita Krishnan Heather Landau George Somlo Nina Sha Source Type: research
Clinical outcomes of pomalidomide ‐based and daratumumab‐based therapies in patients with relapsed/refractory multiple myeloma: A real‐world cohort study in China
ConclusionsIn real-world settings, Pom-based, Dara-based, and DPd therapies exhibited favorable efficacy in patients with RRMM. Dara-based therapy yielded superior clinical response and PFS compared to Pom-based therapy. (Source: Cancer Medicine)
Source: Cancer Medicine - May 3, 2024 Category: Cancer & Oncology Authors: Xiaoyan Han,
Xincheng Jiang,
Jingsong He,
Gaofeng Zheng,
Yaqin Xiong,
Yanling Wen,
Yang Yang,
Donghua He,
Qingxiao Chen,
Yi Zhao,
Yi Li,
Wenjun Wu,
Zhen Cai Tags: RESEARCH ARTICLE Source Type: research
Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant
CONCLUSIONS: Overall analysis of four studies showed a potential benefit for daratumumab in terms of overall survival and progression-free survival and a slight potential benefit in quality of life. Participants treated with daratumumab probably experience increased serious adverse events. There were likely no differences between groups in adverse events (CTCAE grade ≥ 3); however, there are probably more infections (CTCAE grade ≥ 3) in participants treated with daratumumab. We identified six ongoing studies which might strengthen the certainty of evidence in a future update of this review.PMID:38695605 | DOI:10.1002/1...
Source: Cochrane Database of Systematic Reviews - May 2, 2024 Category: General Medicine Authors: Peter Langer Lukas John Ina Monsef Christof Scheid Vanessa Piechotta Nicole Skoetz Source Type: research
The establishment of a multiple myeloma clinical registry in the Asia-Pacific region: The Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR)
CONCLUSION: The APAC MRDR is providing 'real-world' data to participating sites, clinicians and policy-makers to explore factors influencing outcomes and survival, and to support high quality studies. It is already a valuable resource that will continue to grow and support research and clinical collaboration in MM and related diseases across the APAC region.PMID:38698331 | DOI:10.1186/s12874-024-02227-0 (Source: Cell Research)
Source: Cell Research - May 2, 2024 Category: Cytology Authors: Naomi Aoki Pin-Yen Chen Wenming Chen Wee Joo Chng Gin Gin Gan Yeow Tee Goh Jian Hou Jeffrey Huang Kihyun Kim Je Jung Lee Jin Lu Zoe K McQuilten Chang Ki Min Elizabeth Moore Laura Oliver Neil A Waters Cameron Wellard Erica M Wood Su-Peng Yeh Andrew Spencer Source Type: research
Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant
CONCLUSIONS: Overall analysis of four studies showed a potential benefit for daratumumab in terms of overall survival and progression-free survival and a slight potential benefit in quality of life. Participants treated with daratumumab probably experience increased serious adverse events. There were likely no differences between groups in adverse events (CTCAE grade ≥ 3); however, there are probably more infections (CTCAE grade ≥ 3) in participants treated with daratumumab. We identified six ongoing studies which might strengthen the certainty of evidence in a future update of this review.PMID:38695605 | DOI:10.1002/1...
Source: Cochrane Database of Systematic Reviews - May 2, 2024 Category: General Medicine Authors: Peter Langer Lukas John Ina Monsef Christof Scheid Vanessa Piechotta Nicole Skoetz Source Type: research
Cancers, Vol. 16, Pages 1706: Dissecting the Puzzling Roles of FAM46C: A Multifaceted Pan-Cancer Tumour Suppressor with Increasing Clinical Relevance
Manfrini
FAM46C is a well-established tumour suppressor with a role that is not completely defined or universally accepted. Although FAM46C expression is down-modulated in several tumours, significant mutations in the FAM46C gene are only found in multiple myeloma (MM). Consequently, its tumour suppressor activity has primarily been studied in the MM context. However, emerging evidence suggests that FAM46C is involved also in other cancer types, namely colorectal, prostate and gastric cancer and squamous cell and hepatocellular carcinoma, where FAM46C expression was found to be significantly reduced in tumoural versus...
Source: Cancers - April 27, 2024 Category: Cancer & Oncology Authors: Giancarlo Lai Federica De Grossi Ilaria Catusi Elisa Pesce Nicola Manfrini Tags: Review Source Type: research
Sequencing of anti-CD19 therapies in the management of diffuse large B-cell lymphoma
Clin Cancer Res. 2024 Apr 25. doi: 10.1158/1078-0432.CCR-23-1962. Online ahead of print.ABSTRACTSeveral second- and third-line immunotherapeutic options for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ineligible for autologous stem cell transplant are directed against the B-cell antigen CD19. The anti-CD19 monoclonal antibody tafasitamab, paired with the immunomodulator lenalidomide, mediates antibody-dependent cellular toxicity and cellular phagocytosis; the antibody-drug conjugate loncastuximab tesirine delivers the DNA-cross-linking agent tesirine via CD19 binding and internalization; and ...
Source: Cell Research - April 25, 2024 Category: Cytology Authors: Joseph Lownik Jonathan Boiarsky Ruemu Birhiray Akil Merchant Monica Mead Source Type: research
Sequencing of anti-CD19 therapies in the management of diffuse large B-cell lymphoma
Clin Cancer Res. 2024 Apr 25. doi: 10.1158/1078-0432.CCR-23-1962. Online ahead of print.ABSTRACTSeveral second- and third-line immunotherapeutic options for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ineligible for autologous stem cell transplant are directed against the B-cell antigen CD19. The anti-CD19 monoclonal antibody tafasitamab, paired with the immunomodulator lenalidomide, mediates antibody-dependent cellular toxicity and cellular phagocytosis; the antibody-drug conjugate loncastuximab tesirine delivers the DNA-cross-linking agent tesirine via CD19 binding and internalization; and ...
Source: Clinical Cancer Research - April 25, 2024 Category: Cancer & Oncology Authors: Joseph Lownik Jonathan Boiarsky Ruemu Birhiray Akil Merchant Monica Mead Source Type: research
